Cargando…
Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation
Traditional antithrombotic agents commonly share a therapy-limiting side effect, as they increase the overall systemic bleeding risk. A novel approach for targeted antithrombotic therapy is nanoparticles. In other therapeutic fields, nanoparticles have enabled site-specific delivery with low levels...
Autores principales: | Nestele, Jeremy A., Rohlfing, Anne-Katrin, Dicenta, Valerie, Bild, Alexander, Eißler, Daniela, Emschermann, Frederic, Kremser, Marcel, Krutzke, Konstantin, Schäffer, Tilman E., Borst, Oliver, Levi, Moran, Korin, Netanel, Gawaz, Meinrad Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744670/ https://www.ncbi.nlm.nih.gov/pubmed/35008437 http://dx.doi.org/10.3390/ijms23010011 |
Ejemplares similares
-
Anti‐GPVI nanobody blocks collagen‐ and atherosclerotic plaque–induced GPVI clustering, signaling, and thrombus formation
por: Jooss, Natalie J., et al.
Publicado: (2022) -
The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
por: Ungerer, Martin, et al.
Publicado: (2013) -
Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke
por: Reimann, Andreas, et al.
Publicado: (2016) -
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
por: Goebel, Silvia, et al.
Publicado: (2013) -
Comparison of the GPVI inhibitors losartan and honokiol
por: Onselaer, Marie-Blanche, et al.
Publicado: (2019)